Shanghai Sinobioway Sunterra Biotechnology
Shanghai Sinobioway Sunterra Biotechnology specializes in advanced biotechnology, particularly in adoptive cellular therapies aimed at treating solid tumor malignancies. Established through a collaboration between Sinobioway Group, Sunterra Capital, and F1 Oncology, the company is dedicated to developing innovative CAB-CAR-T therapies. To facilitate its research and development efforts, SSSB operates Good Manufacturing Practice (GMP) cell processing facilities in Shanghai, which support clinical research in partnership with leading academic institutions.
1 past transactions
EXUMA Biotech
Venture Round in 2018
EXUMA Biotech Corp. is a clinical-stage biotechnology company focused on the discovery and development of adoptive cellular therapies for solid tumors and hematological malignancies. The company specializes in chimeric antigen receptor-T cell therapy, aiming to enhance the immune system's ability to combat various cancers, including renal cell carcinoma, soft tissue sarcoma, and gastric cancer. Founded in 2015, EXUMA Biotech is headquartered in West Palm Beach, Florida, with additional locations in San Diego, California, Grand Cayman, Cayman Islands, and Shanghai, China. The company is committed to pioneering innovative solutions in cell and gene therapy, leveraging its logic-gated CAR-T platform to improve patient access to these advanced treatment options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.